UnitedHealth’s Earnings Report Could Signal a Turning Point for Managed Care Margins

UnitedHealth’s Q1 earnings report on April 21 could serve as a turning point for its managed care margins. Investors will assess whether the company can sustain margin improvements as Medicare Advantage reimbursement visibility solidifies. Morgan Stanley analyst Erin Wright, who reiterated a Buy rating with a $375 price target, sees this as a pivotal moment following a period of investor fatigue over MA costs and uncertainty. The final Medicare Advantage rate notice has given clearer 2026 reimbursement levels, reinforcing expectations that UNH can continue to improve MA margins. Bernstein SocGen is even more bullish, raising its price target to $411, projecting strong EPS growth as UnitedHealth exits unprofitable MA and Optum Health products. But the company faces a significant risk: 92% of its Medicare Advantage membership is now under review for expanded RADV audits, which begin processing in April 2025.